Background: Inter-individual variation in response to statins (efficacy and toxicity) has been
described and may be due to polymorphisms implicated in drug pharmacokinetics or …

Statins are inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase, a key enzyme in
cholesterol biosynthesis, that are highly effective in reducing plasma low-density lipoprotein …

Background SLCO1B1 polymorphisms are relevant in statin pharmacokinetics. Aim of this
study was to investigate the genetic variability and haplotype profile of SLCO1B1 …

Pharmacogenomics of statin therapy: any new insights in effi... : Current Opinion in
Lipidology Pharmacogenomics of statin therapy: any new insights in efficacy or safety …

Aim: We evaluated the evidence of pharmacogenetic associations with statins in a
systematic review. Methods: Two separate outcomes were considered of interest …

Peyser et al12 randomized 159 patients with a history of statin-induced side effects to
receive SLCO1B1 genotype-informed statin therapy (GIST) or usual care. Patients in the …

Background Patients with dyslipidemia are often treated with statins to reduce lipids and
hence cardiovascular risk, but treatment response is variable, partly due to genetic factors …

Statins are a cornerstone of the pharmacologic treatment and prevention of atherosclerotic
cardiovascular disease. Atherosclerotic disease is a predominant cause of mortality and …

What is known and objective Statins form the backbone of lipid‐lowering therapy for the
prevention of cardiovascular disease. However, there is large interindividual variability in …

Background: Statins are inhibitors of hydroxy-methyl-glutaryl coenzymeA (HMG-CoA)
reductase, the rate-limiting enzyme involved in de novo cholesterol synthesis. The patient …